AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 64
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting goals
Number of subjects: 64
Study 19001303 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone self-management support with nurse care management (ATSM)
Number of subjects: 226
Study 19001303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study 15925121 — intervention group
Group type: EXPERIMENTAL
Intervention: EWSRPT (Early Warning Signs Relapse Prevention Training)
Number of subjects: 124
Study 15925121 — intervention group
Group type: EXPERIMENTAL
Intervention: EWSRPT
Number of subjects: 124
Study 15925121 — intervention group
Group type: COMPARATOR
Intervention: AU (Aftercare as Usual)
Number of subjects: 124
Study 12545029 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal mechanical ventilation
Number of subjects: 722
Study 12545029 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of endotracheal mechanical ventilation
Number of subjects: 722
Study 12545029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity measurement
Number of subjects: 722
Study 12545029 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring in intensive care unit
Number of subjects: 722
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with alexandrite 8 mm spot size
Number of subjects: 12
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with alexandrite 12 mm spot size
Number of subjects: 12
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine cream (ELA-Max) with diode 9 mm spot size
Number of subjects: 12
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: No topical anesthesia with alexandrite 12 mm spot size
Number of subjects: 12
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: No topical anesthesia with diode 9 mm spot size
Number of subjects: 12
Study 10886276 — intervention group
Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 12
Study 10886276 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 12
Study 8778198 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (0.1 IU/kg per day)
Number of subjects: 8
Study 8778198 — intervention group
Group type: COMPARATOR
Intervention: Triiodothyronine (40 micrograms on even dates, 20 micrograms on uneven dates)
Number of subjects: 8
Study 8778198 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone + Triiodothyronine
Number of subjects: 8
Study 1726002 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine once daily (n = 268)
Number of subjects: 637
Study 1726002 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of atenolol once daily (n = 265)
Number of subjects: 637
Study 1726002 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of lacidipine once daily (if needed)
Number of subjects: 637
Study 1726002 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of atenolol once daily (if needed)
Number of subjects: 637
Study 1726002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 mg once daily) added if required after 2 months
Number of subjects: 637
Study 6432553 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bupropion hydrochloride orally with ethanol in orange drink
Number of subjects: 8
Study 6432553 — intervention group
Group type: COMPARATOR
Intervention: 100 mg bupropion hydrochloride orally
Number of subjects: 8
Study 6432553 — intervention group
Group type: COMPARATOR
Intervention: dummy tablet
Number of subjects: 8
Study 31204799 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection
Number of subjects: 0
Study 31204799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rationalization
Number of subjects: 0
Study 31204799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminating on the moral status of impure acts
Number of subjects: 0
Study 29895556 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 1014
Study 29895556 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla‐100)
Number of subjects: 1014
Study 27079985 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis plans (psychiatric advance statements)
Number of subjects: 139
Study 24146086 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm message
Number of subjects: 260
Study 24146086 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 260
Study 22159672 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 100
Study 22159672 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 100
Study 22159672 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 100
Study 22159672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Freight trains at 50 dBA (High)
Number of subjects: 38
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Passenger trains at 50 dBA (High)
Number of subjects: 38
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Automotive trains at 50 dBA (High)
Number of subjects: 38
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate noise level (40 dBA)
Number of subjects: 38
Study 19902241 — intervention group
Group type: COMPARATOR
Intervention: Control night (silent)
Number of subjects: 38
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise during REM sleep
Number of subjects: 38
Study 19902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison (Juniors vs Seniors)
Number of subjects: 38
Study 17563906 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐fluorodeoxyglucose (FDG)‐PET/CT
Number of subjects: 76
Study 15781509 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs) with 2-chloroprocaine
Number of subjects: 50
Study 15781509 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with midazolam, fentanyl, propofol, N(2)O/O(2)/desflurane
Number of subjects: 50
Study 12536163 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional precue (left vs. right)
Number of subjects: 0
Study 12536163 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance information
Number of subjects: 0
Study 10648490 — intervention group
Group type: COMPARATOR
Intervention: Atrial overdrive alone
Number of subjects: 22
Study 10648490 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive + propafenone (600 mg/day)
Number of subjects: 22
Study 8683752 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20 to 40 mcg)
Number of subjects: 95
Study 1812146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 1812146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7051804 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Number of subjects: 0
Study 7051804 — intervention group
Group type: COMPARATOR
Intervention: Delayed adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Number of subjects: 0
Study 31232185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking a sine wave template during training
Number of subjects: 12
Study 31232185 — intervention group
Group type: COMPARATOR
Intervention: 30 additional trials of the target task (control)
Number of subjects: 12
Study 30782863 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity intervention (specific details not provided)
Number of subjects: 69
Study 25259737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral preparation (single dose)
Number of subjects: 20
Study 25259737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral preparation with guaraná (single dose)
Number of subjects: 20
Study 25259737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 25552402 — intervention group
Group type: COMPARATOR
Intervention: Sublingual asenapine 5 mg after ≥ 10 h fasting (Treatment A, reference)
Number of subjects: 26
Study 25552402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B)
Number of subjects: 26
Study 25552402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after ≥ 10 h fasting with a high‐fat meal at 4 h post‐dose (Treatment C)
Number of subjects: 26
Study 25552402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal at 4 h post-dose (Treatment C)
Number of subjects: 26
Study 25552402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B) and after ≥ 10 h fasting with a high‐fat meal at 4 h post-dose (Treatment C)
Number of subjects: 26
Study 23687405 — intervention group
Group type: EXPERIMENTAL
Intervention: CACFP participation
Number of subjects: 0
Study 23687405 — intervention group
Group type: COMPARATOR
Intervention: Non-participating centers (Control)
Number of subjects: 0
Study 21367594 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once-daily
Number of subjects: 1123
Study 21367594 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice-daily
Number of subjects: 1123
Study 19411954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP)
Number of subjects: 125
Study 19411954 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 125
Study 19411954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP) with intellectual disability (ID)
Number of subjects: 125
Study 19411954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy group (CP) without intellectual disability (ID)
Number of subjects: 125
Study 17116685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three antimalarial treatments
Number of subjects: 141
Study 15296910 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic mechanical pleurodesis (TMP)
Number of subjects: 87
Study 15296910 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis (TP)
Number of subjects: 87
Study 11747326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 115
Study 9089939 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion with BAK
Number of subjects: 75
Study 9089939 — intervention group
Group type: COMPARATOR
Intervention: 360 degrees fusion
Number of subjects: 75
Study 8506440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 to 5 mg
Number of subjects: 53
Study 8506440 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 to 100 mg
Number of subjects: 53
Study 8506440 — intervention group
Group type: COMPARATOR
Intervention: ABPM (Ambulatory Blood Pressure Monitoring)
Number of subjects: 53
Study 8506440 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment of blood pressure
Number of subjects: 53
Study 8506440 — intervention group
Group type: COMPARATOR
Intervention: Diastolic ambulatory daily values
Number of subjects: 53
Study 3552917 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate (EO)
Number of subjects: 34
Study 3552917 — intervention group
Group type: COMPARATOR
Intervention: 1% Aethoxysklerol (AS)
Number of subjects: 34
Study 29194927 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer guided sinus floor elevation through lateral window approach with simultaneous implant placement
Number of subjects: 20
Study 29194927 — intervention group
Group type: COMPARATOR
Intervention: Standard sinus elevation procedure through lateral window approach with simultaneous implant placement
Number of subjects: 20
Study 27565012 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dose of alcohol (0.8 g/kg)
Number of subjects: 64
Study 27565012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24845208 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Resistance Training (ERT)
Number of subjects: 60
Study 22324529 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interference protocol
Number of subjects: 167
Study 22324529 — intervention group
Group type: COMPARATOR
Intervention: Interference protocol
Number of subjects: 167
Study 20484246 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP microarray-based aneuploidy screening (n = 85)
Number of subjects: 13
Study 20484246 — intervention group
Group type: COMPARATOR
Intervention: FISH-based aneuploidy screening (n = 75)
Number of subjects: 13
Study 19000028 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 918
Study 19000028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918
Study 16953457 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg co-administered with omeprazole 20 mg
Number of subjects: 24
Study 16953457 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg alone
Number of subjects: 24
Study 14610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered advice message
Number of subjects: 52
Study 14610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 52
Study 14610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Video doctor technology
Number of subjects: 52
Study 10913033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 40% maximum voluntary contraction (MVC)
Number of subjects: 31
Study 10913033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 20% maximum voluntary contraction (MVC)
Number of subjects: 31
Study 8923853 — intervention group
Group type: COMPARATOR
Intervention: Group A (constant dose 4 IU/m2 b.s.)
Number of subjects: 65
Study 8923853 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (4-6-6-6 IU/m2 b.s.)
Number of subjects: 65
Study 8923853 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (4-6-8-8 IU/m2 b.s.)
Number of subjects: 65
Study 8923853 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study 1279169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 13
Study 1279169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3905218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac SR 100 mg/day
Number of subjects: 203
Study 3905218 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 203
Study 3905218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 29879602 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic blood levels (ABLs)
Number of subjects: 34
Study 29879602 — intervention group
Group type: COMPARATOR
Intervention: No antipsychotic blood levels (ABLs)
Number of subjects: 34
Study 26444072 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI-007 60 mg
Number of subjects: 335
Study 26444072 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 335
Study 26444072 — intervention group
Group type: COMPARATOR
Intervention: ITI-007 120 mg
Number of subjects: 335
Study 26444072 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI-007 60 mg and 120 mg
Number of subjects: 335
Study 25748317 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic supplementation with a mobile stick on a rough surface
Number of subjects: 11
Study 25748317 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic supplementation with a mobile stick on a slippery surface
Number of subjects: 11
Study 25748317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed stick condition
Number of subjects: 11
Study 25748317 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 11
Study 23743471 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (400 micrograms)
Number of subjects: 125
Study 23743471 — intervention group
Group type: COMPARATOR
Intervention: Synthetic osmotic cervical dilator
Number of subjects: 125
Study 20652004 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 36
Study 20652004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17645503 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test)
Number of subjects: 41688
Study 17645503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 41688
Study 16153914 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 10)
Number of subjects: 30
Study 16153914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine, 0.5 microg x kg x min (n = 9)
Number of subjects: 30
Study 16153914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 0.5 microg x kg x min (n = 11)
Number of subjects: 30
Study 12580267 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg(‐1) of droperidol
Number of subjects: 120
Study 12580267 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg/kg(‐1) of ondansetron
Number of subjects: 120
Study 12580267 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study 9874808 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100, 400, or 800 mg)
Number of subjects: 0
Study 9874808 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg)
Number of subjects: 0
Study 9874808 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100-800 mg)
Number of subjects: 0
Study 8684687 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 30
Study 1904891 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide or Flecainide
Number of subjects: 2371
Study 1904891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2371
Study 6352448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath technique
Number of subjects: 40
Study 6352448 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 40
Study 30784839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation (HS)
Number of subjects: 82
Study 30784839 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation with birth model (SBM)
Number of subjects: 82
Study 30784839 — intervention group
Group type: COMPARATOR
Intervention: Video demonstration (VD)
Number of subjects: 82
Study 30784839 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 82
Study 28903767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary containing amphoteric tenside (WO3191) after metronidazole treatment
Number of subjects: 0
Study 28903767 — intervention group
Group type: COMPARATOR
Intervention: Pessary containing lactic acid (Control)
Number of subjects: 0
Study 26965694 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erythropoiesis receptor activator (C.E.R.A.) once-monthly
Number of subjects: 2060
Study 25318787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial hydration (RH)
Number of subjects: 216
Study 25318787 — intervention group
Group type: COMPARATOR
Intervention: No remedial hydration (control)
Number of subjects: 216
Study 22074122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily for 24 weeks
Number of subjects: 170
Study 22074122 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily for 24 weeks
Number of subjects: 170
Study 19765769 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (20 mEq) ingested daily by International Space Station crew members
Number of subjects: 30
Study 19765769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 17472097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-activation before the IAT categorization task
Number of subjects: 0
Study 17472097 — intervention group
Group type: COMPARATOR
Intervention: Implicit Association Test (IAT)
Number of subjects: 0
Study 15260460 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 128
Study 15260460 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (Control)
Number of subjects: 128
Study 12171961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileoanal reservoir (IAR)
Number of subjects: 40
Study 12171961 — intervention group
Group type: COMPARATOR
Intervention: Control tissue (ileal)
Number of subjects: 40
Study 11743486 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 436
Study 11743486 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.1%
Number of subjects: 436
Study 9429034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-made diet
Number of subjects: 20
Study 9429034 — intervention group
Group type: COMPARATOR
Intervention: Commercial diet
Number of subjects: 20
Study 8508666 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1000 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131
Study 8508666 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131
Study 8508666 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131
Study 8508666 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene 75 micrograms + ethinyloestradiol 30 micrograms
Number of subjects: 131
Study 2872808 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 138
Study 2872808 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin with beta blocker plus diuretic
Number of subjects: 138
Study 2872808 — intervention group
Group type: COMPARATOR
Intervention: Placebo with beta blocker plus diuretic
Number of subjects: 138
Study 2872808 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin with other antihypertensive drugs
Number of subjects: 138
Study 2872808 — intervention group
Group type: COMPARATOR
Intervention: Placebo with other antihypertensive drugs
Number of subjects: 138
Study 31969547 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) group: Nanoseal application at baseline and 1-5 months
Number of subjects: 129